Listing of Claims

- 1. (Amended) A method for <u>preventing inhibiting</u> immunoglobulin-induced toxicity <u>in a subject</u>, <u>resulting from immunoglobulin immunotherapy in a subject</u> comprising administering an immunoglobulin molecule to <u>a</u> [[the]] subject, <u>said</u> [[the]] immunoglobulin molecule having a variable region and a constant region, <u>said</u> [[the]] immunoglobulin molecule being modified prior to administration by structurally altering multiple toxicity-associated regions in the <u>CH</u>₂ [[CH2]] domain <u>of said constant region</u> so that immunoglobulin-induced toxicity is inhibited <u>in said subject</u>, <u>wherein said multiple toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH₂ domain.</u>
- 2. (Amended) A method for <u>preventing inhibiting</u> immunoglobulin-induced toxicity <u>in a subject</u>, <u>resulting from immunoglobulin immunotherapy in a subject</u> comprising administering a structurally altered antibody to <u>a</u> [[the]] subject, <u>said</u> [[the]] structurally altered antibody comprising a variable region and a constant region, <u>wherein</u> multiple toxicity-associated regions in the <u>CH</u>₂ [[CH2]] domain <u>of said constant region are</u> [[being]] modified so as to render <u>said</u> [[the]] constant region unable to mediate an antibody dependent cellular cytotoxicity response or activate complement, thereby inhibiting immunoglobulin-induced toxicity, <u>resulting from immunotherapy</u> <u>wherein said multiple toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH₂ domain.</u>
- 3. (Amended) A method for <u>preventing</u> <u>inhibiting</u> immunoglobulin-induced toxicity <u>in a subject</u>, <u>resulting from immunotherapy in a subject</u> comprising administering an Ig fusion protein to <u>a</u> [[the]] subject, <u>said</u> [[the]] Ig fusion protein having multiple structurally altered toxicity-associated regions in the <u>CH</u>₂ [[CH2]] domain <u>of the constant region of said Ig fusion protein</u>, <u>wherein said multiple structurally altered toxicity-associated regions comprise amino acids 231-238 and <u>amino acids 310-331 of said CH</u>₂ <u>domain</u>.</u>
- 4. (Amended) A method for <u>preventing inhibiting</u> immunoglobulin-induced toxicity <u>in a subject</u>, <u>resulting from immunotherapy in a subject</u> comprising administering an lg fusion protein to a [[the]] subject, <u>said</u> [[the]] Ig fusion protein comprising a modified constant region, the modification being a structural alteration in multiple toxicity-associated regions within the <u>CH</u>₂ [[CH2]] domain <u>of said constant region</u>, wherein said multiple toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH₂ domain.

